Genecast 臻和

DU Bo

Chief Executive Officer
MA Guosheng

Executive Vice President
ZUO Honggang

Chief Financial Officer
CHEN Weizhi

Chief Scientific Officer

DU Bo

Chief Executive Officer

Mr. DU Bo is a pioneer in the NGS precision medicine industry in China. He founded China’s first NGS reagent company, Covestro. Mr. DU is currently a member of the CSCO and a member of the Clinical Research Professional Committee of Beijing Cancer Society. He has well-rounded and extensive experience in pharmaceuticals and NGS, and has a distinguished strategic vision in our business.

MA Guosheng

Executive Vice President

Mr. MA Guosheng previously worked in senior sales leadership positions for Bristol-Myers Squibb, Sanofi Aventis, Merck Serono and other well-known multinational pharmaceutical companies, and has more than 20 years of sales and marketing management experience in the field of oncology drugs.

ZUO Honggang

Chief Financial Officer

Mr. ZUO Honggang has more than 20 years of extensive domestic and overseas experience in strategic planning, financial management, mergers and acquisitions and capital markets. He has held important positions in well-known companies such as PwC, GE and Goldman Sachs. Mr. Zuo brings industry-leading capital markets and corporate finance experience.

CHEN Weizhi

Chief Scientific Officer

Dr. CHEN Weizhi has a combined background in medicine and molecular biology and more than 20 years of experience in biotechnology research in both China and the U.S. Dr. CHEN has gained extensive knowledge in all aspects of high-throughput genomics research with a specialty in NGS applications in clinical space. She is the inventor of 38 patents globally, many of which are related to our key products and services and technologies. Previously, she served as the head of R&D in GENEWIZ China and Simcere Diagnostics.

Inspection institute qualification

Corporate certificate

Clinical Gene Amplification Laboratory Technology Acceptance Certificate
CAP Accredited, ISO15189 Accredited
Practice License of Medical Institution
Biosafety Laboratory Record Certificate

Corporate certificate

ISO15189 Accredited

CAP Accredited

SCCL EQA Certificate

Jiangsu Certification for EQA

NCCL EQA Certificate

High-tech Enterprise.

NCCL EQA Certificate

Jiangsu Certification for EQA

SCCL EQA Certificate

NCCL EQA Certificate

JIANGSU CERTIFICATION FOR EQA

NCCL EQA Certificate

CAP Accredited

High-tech Enterprise.

Zhongguancun High-tech Enterprise.

NGS Qualification

ARMS Qualification

High-tech Enterprise.

NCCL EQA Certificate

SCCL EQA Certificate

NCCL EQA Certificate

2014/11

Genecast Biotechnology was established in the PRC.

2016/01

We launched Genecast Comprehensive.

2017/06

We launched Genecast PD-L1.

2017/07

We launched Genecast Lung and Genecast CRC.

2017/12

We were awarded National High-tech Enterprise Certificate.

2018/04

Wuxi Genecast Laboratory obtained the Practice License of Medical Institution.

2018/09

We launched MammaPrint^® licensed from Agendia in China.

2018/10

Wuxi laboratory was certified by U.S. College of American Pathologist.

2018/12

Taizhou manufacturing facility obtained the YY/T0287- 2017 idt ISO 13485:2016 certification.

2019/09

Wuxi laboratory was certified as a PCR laboratory to carry out “tumor-related genetic testing activities (with conventional ARMS method and NGS method)”.

2019/09

Awarded 2019 EY Fudan China Most Promising Enterprises Award by Ernst & Young.

2019/11

We launched Genecast Lung TILs.

2020/04

We launched Genecast RNA Fusion Focus.

2020/11

We launched Genecast MRD – Lung.

2020/11

We launched TumorX with the participation of Zhejiang University.

2021/02

We obtained our first IVD product registration certificate from NMPA for Genecast IVD – KNBP.

2021/07

We launched Genecast Genius G1 and Genecast INTEGRO V1.0, both certified by NMPA.

2021/08

We launched Immunoscore^® licensed from Veracyte in China.

2021/11

We launched Tissue of Origin^® in China.

2022/02

We launched Genecast MRD – CRC.

2022/03

We obtained CE marking for 5 Genecast IVD products.

2022/06

We launched Genecast MRD – Comprehensive.

2022/07

Our new Taizhou manufacturing facility commenced operations.

2022/08

We received a Class II medical device registration certificate from Jiangsu MPA for our Genecast Genius X.

2014/11

Genecast Biotechnology was established in the PRC.

2016/01

We launched Genecast Comprehensive.

2017/06

We launched Genecast PD-L1.

2017/07

We launched Genecast Lung and Genecast CRC.

2017/12

We were awarded National High-tech Enterprise Certificate.

2018/04

Wuxi Genecast Laboratory obtained the Practice License of Medical Institution.

2018/09

We launched MammaPrint^® licensed from Agendia in China.

2018/10

Wuxi laboratory was certified by U.S. College of American Pathologist.

2018/12

Taizhou manufacturing facility obtained the YY/T0287- 2017 idt ISO 13485:2016 certification.

2019/09

Wuxi laboratory was certified as a PCR laboratory to carry out “tumor-related genetic testing activities (with conventional ARMS method and NGS method)”.

2019/09

Awarded 2019 EY Fudan China Most Promising Enterprises Award by Ernst & Young.

2019/11

We launched Genecast Lung TILs.

2020/04

We launched Genecast RNA Fusion Focus.

2020/11

We launched Genecast MRD – Lung.

2020/11

We launched TumorX with the participation of Zhejiang University.

2021/02

We obtained our first IVD product registration certificate from NMPA for Genecast IVD – KNBP.

2021/07

We launched Genecast Genius G1 and Genecast INTEGRO V1.0, both certified by NMPA.

2021/08

We launched Immunoscore^® licensed from Veracyte in China.

2021/11

We launched Tissue of Origin^® in China.

2022/02

We launched Genecast MRD – CRC.

2022/03

We obtained CE marking for 5 Genecast IVD products.

2022/06

We launched Genecast MRD – Comprehensive.

2022/07

Our new Taizhou manufacturing facility commenced operations.

2022/08

We received a Class II medical device registration certificate from Jiangsu MPA for our Genecast Genius X.